Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMEC-II: Risk-adapted Chemotherapy for Relapsed Germ Cell Tumours
NCT06309732Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jul 2006
- Primary completion
- Jun 2013
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim, actinomycin D, methotrexate, etoposide, Cisplatin micelle injection (HA132) in germ cell tumor (GCT), sponsored by Queen Mary University of London. Started Jul 2006; status: completed.
02
Drugs
pegfilgrastimactinomycin DmethotrexateetoposideCisplatin micelle injection (HA132)
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT06309732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309732.